Trial results for the PEACH2 study, focused on promoting engagement and COVID-19 testing, were posted on ClinicalTrials.gov on 2026-02-23. The study enrolled 290 participants with COVID-19, targeting individuals affected by diabetes.
Background
COVID-19 continues to be a public health concern, with ongoing efforts to encourage testing and vaccination to mitigate its spread and severity. Individuals with underlying conditions, such as diabetes, are often at higher risk for severe outcomes from COVID-19, making targeted community-based interventions crucial for health promotion and disease management. Promoting engagement in health behaviors, including timely testing when symptomatic and vaccination, is a key strategy to protect vulnerable populations and reduce community transmission.
Trial design
The PEACH2 study, identified as Phase NA, was a community-based study that enrolled 290 participants. The trial focused on individuals affected by diabetes and aimed to promote engagement and COVID-19 testing for health. Participants were randomized into either the Project PEACH2 Intervention Arm or a Control Group. The intervention period lasted for 16 weeks, with participants followed for a total of 12 months.
Key results
The trial results provided data on two key measurements:
- Number of Participants With Symptoms Who Use a COVID-19 Test:
- In the Project PEACH2 Intervention group, the reported counts were 16, 3, 6, and 9 participants.
- In the Control Group, the reported counts were 17, 10, 15, and 12 participants.
- Percent of Participants Receiving COVID-19 Vaccination:
- In the Project PEACH2 Intervention group, the reported percentages were 83.4% and 85.6% of participants.
- In the Control Group, the reported percentages were 82.1% and 83.1% of participants.
What this means
The posted results from the PEACH2 study offer insights into participant engagement in COVID-19 testing and vaccination within a community-based setting targeting individuals with diabetes. The data indicate that a notable percentage of participants across both the intervention and control groups received COVID-19 vaccination, with rates ranging from approximately 82.1% to 85.6%. Regarding COVID-19 testing among symptomatic participants, the reported counts varied across measurements for both the intervention and control groups. Without further statistical analysis or context on the total number of symptomatic individuals, it is challenging to determine the specific impact of the PEACH2 intervention on testing behaviors or vaccination rates. The findings provide baseline data on health behaviors in this specific population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06141850, titled "Promoting Engagement and COVID-19 Testing for Health", were posted on 2026-02-23 on clinicaltrials.gov.